On April 15, 2025, President Trump issued an Executive Order (EO) titled “Lowering Drug Prices by Once Again Putting America First”, introducing several concepts aimed at lowering the cost of prescription medications in the United States...

At ProAct, we continue to enable affordable access to biosimilars and help ensure a smooth transition for patients starting these innovative products. Our thoughtful and comprehensive approach to include inflammatory biosimilars on our ...

On March 20, 2025, Johnson & Johnson’s Tremfya® (guselkumab) received FDA approval for a label expansion for the treatment of Crohn’s Disease (CD). Tremfya® is the first and only interleukin (IL)-23 inhibitor offering both subcutaneous ...

A new oral weight loss medication by Eli Lilly, Orforglipron, showed promising results in a phase 2 trial published in the New England Journal of Medicine in June 2023. The highest dose of the drug resulted in approximately 15% weight loss ...

On March 7, 2025, the US Food and Drug Administration (FDA) approved Celltrion’s Omlyclo® (omalizumab-igec) as the first interchangeable biosimilar to Novartis’ Xolair® (omalizumab). Omlyclo is approved for the same indications as ...